167 related articles for article (PubMed ID: 16457690)
1. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.
Kasukabe T; Okabe-Kado J; Kato N; Sassa T; Honma Y
Breast Cancer Res; 2005; 7(6):R1097-110. PubMed ID: 16457690
[TBL] [Abstract][Full Text] [Related]
2. Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.
Kasukabe T; Okabe-Kado J; Honma Y
Cancer Sci; 2008 Aug; 99(8):1693-8. PubMed ID: 18754885
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
Kasukabe T; Okabe-Kado J; Haranosono Y; Kato N; Honma Y
Int J Oncol; 2013 Feb; 42(2):767-75. PubMed ID: 23255002
[TBL] [Abstract][Full Text] [Related]
4. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Kasukabe T; Okabe-Kado J; Kato N; Honma Y; Kumakura S
Int J Oncol; 2015 Feb; 46(2):841-8. PubMed ID: 25405645
[TBL] [Abstract][Full Text] [Related]
5. Effects of rapamycin on cell apoptosis in MCF-7 human breast cancer cells.
Tengku Din TA; Seeni A; Khairi WN; Shamsuddin S; Jaafar H
Asian Pac J Cancer Prev; 2014; 15(24):10659-63. PubMed ID: 25605156
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.
Maniwa Y; Kasukabe T; Kumakura S
Int J Oncol; 2015 Aug; 47(2):473-80. PubMed ID: 26046133
[TBL] [Abstract][Full Text] [Related]
8. Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
Takahashi T; Honma Y; Miyake T; Adachi K; Takami S; Okada M; Kumanomidou S; Ikejiri F; Jo Y; Onishi C; Kawakami K; Moriyama I; Inoue M; Tanaka J; Suzumiya J
Int J Oncol; 2015 Apr; 46(4):1801-9. PubMed ID: 25672400
[TBL] [Abstract][Full Text] [Related]
9. Cotylenin A, a differentiation-inducing agent, and IFN-alpha cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice.
Honma Y; Ishii Y; Yamamoto-Yamaguchi Y; Sassa T; Asahi K
Cancer Res; 2003 Jul; 63(13):3659-66. PubMed ID: 12839956
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of cotylenin A plus interferon-alpha: possible therapeutic agents against ovary carcinoma.
Honma Y; Kasukabe T; Yamori T; Kato N; Sassa T
Gynecol Oncol; 2005 Dec; 99(3):680-8. PubMed ID: 16112179
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents.
Honma Y; Akimoto M
Cancer Sci; 2007 Nov; 98(11):1643-51. PubMed ID: 17645578
[TBL] [Abstract][Full Text] [Related]
12. Cotylenin A-induced differentiation is independent of the transforming growth factor-beta signaling system in human myeloid leukemia HL-60 cells.
Matsunawa M; Ishii Y; Kasukabe T; Tomoyasu S; Ota H; Honma Y
Leuk Lymphoma; 2006 Apr; 47(4):733-40. PubMed ID: 16690533
[TBL] [Abstract][Full Text] [Related]
13. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
14. Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
Du J; Sun Y; Lu YY; Lau E; Zhao M; Zhou QM; Su SB
Anticancer Res; 2017 Nov; 37(11):6141-6151. PubMed ID: 29061795
[TBL] [Abstract][Full Text] [Related]
15. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
[TBL] [Abstract][Full Text] [Related]
18. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
Chen J; Zeng J; Xin M; Huang W; Chen X
Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
[TBL] [Abstract][Full Text] [Related]
19. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
20. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]